Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where G. Lux is active.

Publication


Featured researches published by G. Lux.


Gastroenterology | 1978

Effects of Vasoactive Intestinal Peptide on Resting and Pentagastrin-Stimulated Lower Esophageal Sphincter Pressure

Wolfram Domschke; G. Lux; Domschke S; U. Strunz; Stephen R. Bloom; Erich Wünsch

Vasoactive intestinal peptide (VIP) administered as an intravenous infusion at different doses (0.8, 1.6, and 3.2 micrograms per kg per hr, respectively) inhibited dose-dependently the response of the lower esophageal sphincter to an intravenous injection of pentagastrin (0.6 microgram per kg) in 4 healthy volunteers. Inhibition ranged from about 20% (not significant) with the low dose to about 55% (P less than 0.05) with the high dose. On the other hand, the VIP doses employed did not substantially decrease basal lower esophageal sphincter pressure. Calculated on the basis of plasma levels of the respective peptides, the inhibitory effect of VIP was about one-third of that of secretin. Even at the smallest dose of VIP, plasma levels of radioimmunoassayable VIP (20 to 100 pmoles per liter) markedly exceeded those encountered normally (1 to 19 pmoles per liter). So, the data presented do not support the suggestion that normally circulating VIP essentially contributes to the physiological regulation of the lower esophageal sphincter pressure; they do not exclude, however, such a role for locally released VIP.


Langenbecks Archiv f�r Chirurgie | 1985

Therapeutische Pankreasgangocclusion bei chronischer Pankreatitis: Klinische, exokrine und endokrine Konsequenzen bei 12monatiger Nachbeobachtung

Michael Ulrich Schneider; G. Lux; Ch. Gebhardt; Richard Meister; J. Pichl; Gerhard Heptner; H. Knorr; Th. Rödle; S. Domschke; W. Domschke

SummaryTherapeutic pancreatic duct occlusion (PDO) is applied to preserve endocrine pancreatic function by atrophizing and thus eliminating chronically inflamed exocrine pancreatic parenchyma. So far, efficient and lasting elimination of exocrine parenchyma is brought about only by intraoperative PDO upon partial duodenopancreatectomy. While partial duodenopancreatectomy itself reduces endocrine pancreatic function by about 40%, intraoperative PDO does not further impair endocrine function. Endocrine function is not affected at all by endoscopic PDO, which has to be improved, however, concerning its eliminatory effect on exocrine pancreatic parenchyma.ZusammenfassungZiel der therapeutischen Pankreasgangocclusion (PGO) bei chronischer Pankreatitis ist die Erhaltung der endokrinen Restfunktion durch Atrophisierung und somit Eliminierung des die chronische Entzündung unterhaltenden exokrinen Pankreasparenchyms. Eine effiziente und anhaltende Eliminierung des exokrinen Parenchyms wird bislang nur durch intraoperative PGO im Rahmen der partiellen Duodenopankreatektomie erreicht. Die endokrine Pankreasfunktion wird durch partielle Pankreasresektion im Rahmen der partiellen Duodenopankreatektomie um ca. 40% reduziert, durch intraoperative PGO jedoch nicht weiter beeinflußt. Keinerlei Reduktion der endokrinen Pankreasfunktion fand sich nach endoskopischer PGO, deren Effekt auf die Eliminierung des exokrinen Parenchyms allerdings noch verbesserungsbedürftig ist.


Coloproctology | 2001

Langzeitverlauf der primär konservativ behandelten akuten Sigmadivertikulitis Eine retrospektive Analyse

Ralf Nemitz; Stefan Redlin; Hans-Joachim Meyer; G. Lux; Boris Pfaffenbach

ZusammenfassungFragestellung: Ziel der vorliegenden Studie war es, den Langzeitverlauf bei Patienten mit primär konservativ behandelter Sigmadivertikulitis zu erfassen. Patienten und Methodik: In den Jahren 1991–1995 wurden in unserer Klinik 88 Patienten (57 Frauen, 31 Männer, durchschnittliches Alter 65,7 Jahre) mit einer akuten Sigmadivertikulitis primär konservativ behandelt. In einer retrospektiven Analyse wurden das klinische Beschwerdebild sowie die diagnostischen und therapeutischen Maßnahmen 1998 erfasst. Ergebnisse: Bei 76,1% der Patienten (n = 67) verlief die Sigmadivertikulitis unkompliziert. Die Rezidivrate während des Beobachtungszeitraums betrug 42,6% (n = 26). Bei 23,9% der Patienten (n = 21) wies die Sigmadivertikulitis Komplikationen auf. Die Rezidivrate dieser Patientengruppe betrug 75%. 76,2% dieser Patienten (n = 16) wurden im Anschluss an die internistische Therapie operiert. Nicht letale Komplikationen traten bei 14,3% (n = 5) der insgesamt 35 operierten Patienten auf. Zwei Patienten (5,7%) verstarben postoperativ. 93,7% (n = 15) der initial operierten Patienten blieben postoperativ beschwerdefrei. Schlussfolgerung: Bei komplizierter Sigmadivertikulitis besteht die Indikation zur operativen Therapie. Eine konservative Therapie ist bei unkomplizierten Verläufen der Sigmadivertikulitis gerechtfertigt. In Anbetracht der hohen Rezidivrate kann allerdings individuell bereits nach dem ersten Divertikulitisschub die Indikation zur elektiven Sigmaresektion überprüft werden.AbstractAim: The aim of this study was to analyze the outcome of patients with sigmoid diverticulitis who primarily received conservative treatment. Method: During the years 1991–1995 88 patients (57 female, 31 male, average age 65.7 years) received conservative treatment for sigmoid diverticulitis in our clinic. Performing a retrospective analysis in 1998 we investigated clinical symptoms as well as diagnostic and therapeutic approaches. Results: 76.1% (67/88) of the patients showed no complications. During the observation period a relapse occurred in 42.6% of the patients (26/61). Complications were detected in 23.9% of the patients (21/88). Within the group of patients with complications, 75% relapsed and 76.2% underwent surgery following medical therapy. 14.3% of the patients (5/35) receiving surgical treatment had non-fatal complications. Two patients (5.7%) died postoperatively. 15 out of the 16 initially operated patients (93.7%) remained symptom-free following surgery. Conclusions: Patients with complicated sigmoid diverticulitis should receive surgical treatment, whereas conservative treatments is indicated in uncomplicated cases. In light of the high rate of recurrence, however, elective sigmoid resection should be considered individually following a diagnosis of diverticulitis.


Endoscopy | 1986

Upper gastrointestinal bleeding as an unusual presentation of a duodenal carcinoid.

E. Gencsi; E. Lux; B. Kaduk; W. Roedl; H. Schmidt; Ch. Gebhardt; G. Lux

Carcinoid tumors may develop in any part of the gastrointestinal tract. They constitute 1.5% of all gastrointestinal tumors (1). The duodenum is one of the least common sites of this tumor, with a reported incidence varying between 0.2% and 8.9% (2, 3). We report on a case of a bleeding duodenal carcinoid in a patient who underwent bilateral nephrectomy for malignant hypertension.


Gastroenterology | 1980

Furan H2-antagonist ranitidine inhibits pentagastrin-stimulated gastric secretion stronger than cimetidine.

Wolfram Domschke; G. Lux; Domschke S


Endoscopy | 1997

Treatment of bleeding esophageal varices with cyanoacrylate and polidocanol, or polidocanol alone : Results of a prospective study in an unselected group of patients with cirrhosis of the liver

G. Lux; M. Retterspitz; U. Stabenow-Lohbauer; M. Langer; A. Altendorf-Hofmann; T. Bozkurt


Endoscopy | 1983

The importance of ERCP for the surgical tactic in haemorrhagic necrotizing pancreatitis (preliminary report).

Ch. Gebhardt; J. F. Riemann; G. Lux


Gastroenterology | 1978

13-NLE-motilin and interdigestive motor and electrical activity of human small intestine

G. Lux; U. Strunz; S. Domschke; J. Femppel; Rösch W; Wolfram Domschke


Endoskopie Heute | 2002

Virtuelle Koloskopie - bereit, sich im Alltag zu bewähren? - Fragen durch den Gastroenterologen -

G. Lux; Ute Stabenow-Lohbauer; Mechtild Langer


Gastroenterology | 2001

Clinical significance of biliary microlithiasis in patients with dyspepsia

Boris Pfaffenbach; Christine Stanull; Mechtild Langer; Ute Stabenow-Lohbauer; G. Lux

Collaboration


Dive into the G. Lux's collaboration.

Top Co-Authors

Avatar

Ch. Gebhardt

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gerhard Heptner

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

H. Knorr

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

J. Pichl

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Michael Ulrich Schneider

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Th. Rödle

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

W. Domschke

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Richard Meister

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge